F

F

inancing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and Oriza

由奥博资本领投，TCGX、LAV、辰德资本以及现有投资者SCGC和元禾参与融资。

Proceeds will advance

收益将增加

multi-asset pipeline including AC-101, a leading RIPK2 inhibitor for Ulcerative Colitis

多资产管道，包括AC-101，一种领先的用于溃疡性结肠炎的RIPK2抑制剂

NEW YORK and SUZHOU, China

纽约和中国苏州

,

，

May 18, 2026

2026年5月18日

/PRNewswire/ -- Accro Bioscience Inc. ('Accro Bioscience'), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulatory cell death for immune mediated diseases,

/PRNewswire/ -- Accro Bioscience Inc.（“Accro Bioscience”），一家临床阶段的生物技术公司，致力于开发针对调节性细胞死亡分子机制的新型疗法，用于免疫介导的疾病，

announced the closing of its $50 million Series C financing. The round was led by OrbiMed, with participation from TCG Crossover ('TCGX'), LAV, Cenova Capital, and existing investors Shenzhen Capital Group ('SCGC') and Oriza Holdings ('Oriza').

宣布完成5000万美元的C轮融资。本轮融资由奥博资本领投，TCG Crossover（“TCGX”）、LAV、辰德资本以及现有投资者深圳资本集团（“SCGC”）和元禾控股（“Oriza”）跟投。

Proceeds from the financing will fund the Phase IIb clinical trial of AC-101, a leading RIPK2 inhibitor, for the treatment of Ulcerative Colitis (UC), and other novel therapeutic candidates for I&I diseases.

融资所得将用于资助领先的RIPK2抑制剂AC-101治疗溃疡性结肠炎（UC）的IIb期临床试验，以及其他用于治疗I&I疾病的新型候选疗法。

Dr. Xiaohu (Jason) Zhang, Co-founder and CEO of Accro Bioscience, said

Accro Bioscience联合创始人兼首席执行官张小虎（Jason）博士表示

:

：

'We at Accro Bioscience are focused on our mission of delivering innovative oral treatments for the millions of patients living with immune mediated diseases. I'm grateful to our investors who share our vision and have supported us continuously.'

“我们Accro Bioscience致力于为数百万免疫介导疾病患者提供创新的口服治疗。我非常感谢与我们拥有相同愿景并持续支持我们的投资者。”

Steven Wang, Ph.D., CFA, Partner at OrbiMed, said:

王史蒂文博士，CFA，奥博资本合伙人，表示：

'We are highly impressed by Accro Bioscience's innovative pipeline. The team's scientific acumen and track record of strong execution were instrumental in our decision to invest. OrbiMed is excited to partner with Accro to accelerate their global clinical development.'

“我们对Accro Bioscience的创新研发管线印象深刻。该团队的科学洞察力和强大的执行记录是我们决定投资的关键因素。OrbiMed很高兴与Accro合作，加速其全球临床开发。”

About AC-101

关于AC-101

AC-101 is a novel, selective RIPK2 inhibitor being developed for the treatment of moderate-to-severe Ulcerative Colitis (UC). Receptor interacting protein kinase 2 (RIPK2) is a key mediator in the NOD signaling pathway, and dysregulation of NOD/RIPK2 is implicated in several inflammatory and autoimmune diseases.

AC-101 是一种新型、选择性的 RIPK2 抑制剂，正在开发用于治疗中度至重度溃疡性结肠炎 (UC)。受体相互作用蛋白激酶 2 (RIPK2) 是 NOD 信号通路中的关键介质，NOD/RIPK2 的失调与多种炎症和自身免疫疾病有关。

AC-101 was developed from Accro .

AC-101是由Accro开发的。

Bioscience's

生物科学的

proprietary drug discovery platform targeting regulatory cell death and inflammation. AC-101 has completed Phase I studies in healthy volunteers in Australia and China, demonstrating a favorable safety and PK/PD profile. A Phase Ib/IIa proof-of-concept study in Chinese patients with moderate-to-severe UC has been completed.

专有的药物发现平台，靶向调节细胞死亡和炎症。AC-101 已在澳大利亚和中国的健康志愿者中完成了 I 期研究，显示出良好的安全性和药代动力学/药效学特性。一项针对中重度溃疡性结肠炎（UC）中国患者的 I b/II a 期概念验证研究已经完成。

The Company has received the IND clearance from U.S. FDA for a Phase II clinical trial..

公司已收到美国FDA关于二期临床试验的IND许可。

About Accro Bioscience

关于Accro生物科学

Accro Bioscience Inc. is a clinical-stage biotechnology company pioneering the discovery, development and commercialization of novel therapeutics for inflammatory and autoimmune diseases, by targeting molecular mechanisms of regulatory cell death. The company's robust pipeline of first- and best-in-class compounds offers the potential for innovative, paradigm-shifting therapies..

Accro Bioscience Inc. 是一家临床阶段的生物技术公司，致力于通过靶向调节细胞死亡的分子机制，发现、开发和商业化用于炎症和自身免疫性疾病的新型疗法。公司强大的首创新药和最佳创新药候选管线有望带来创新且具有颠覆性的治疗方案。

For more information, please visit

更多信息，请访问

www.accropeutics.com

www.accropeutics.com

.

。

About OrbiMed

关于奥博资本

OrbiMed is a leading healthcare investment firm, with over $19 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies.

OrbiMed是一家领先的医疗保健投资公司，管理着超过190亿美元的资产。OrbiMed通过私募股权基金、公开股权基金以及特许权/信贷基金，在全球范围内对医疗保健行业进行投资，从初创企业到大型跨国公司均有涉及。OrbiMed致力于成为首选的资本提供者，提供定制的融资解决方案和广泛的全球团队资源，以帮助建立世界级的医疗保健公司。

OrbiMed's team of over 130 professionals is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets..

奥博资本超过130人的团队分布在纽约、伦敦、旧金山、上海、香港、孟买、赫兹利亚及其他主要全球市场。

For more information, please visit

更多信息，请访问

www.orbimed.com

www.orbimed.com

.

。

SOURCE Accro Bioscience Inc.

来源：Accro Bioscience Inc.

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示